Forte Antonio J, Boczar Daniel, Huayllani Maria T, Anastasiadis Panos Z, McLaughlin Sarah A
Division of Plastic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Lymphat Res Biol. 2022 Feb;20(1):3-6. doi: 10.1089/lrb.2020.0011. Epub 2021 Mar 19.
Lymphangiogenic growth factors, such as vascular endothelial growth factor (VEGF)-D, are subjects of interest in studies of targeted therapies in lymphedema treatment. We conducted a systematic review assessing the use of VEGF-D as a targeted therapy in lymphedema treatment. We hypothesized that VEGF-D was a promising therapy to induce lymphangiogenesis. Our search yielded 90 studies in the literature, but only 4 articles fulfilled our study eligibility criteria, and they were all experimental studies using viral gene transfer. The majority of the studies were conducted on small animals (mice) and investigated the effects of VEGF-D on lymph node transfer. All authors agreed about VEGF-D's lymphangiogenic potential, but they noticed that VEGF-C induced a superior lymphangiogenesis, and one study noticed that VEGF-D induced seroma. The publications assessing the use of VEGF-D as a targeted therapy in lymphedema treatment were able to demonstrate its lymphangiogenic potential. Nonetheless, further studies are still necessary to investigate VEGF-D's efficacy and safety in lymphedema treatment on patients.
淋巴管生成生长因子，如血管内皮生长因子（VEGF）-D，是淋巴水肿治疗靶向治疗研究中的关注对象。我们进行了一项系统评价，评估VEGF-D作为淋巴水肿治疗靶向治疗的应用。我们假设VEGF-D是诱导淋巴管生成的一种有前景的治疗方法。我们的检索在文献中得到了90项研究，但只有4篇文章符合我们的研究纳入标准，且它们均为使用病毒基因转移的实验研究。大多数研究是在小动物（小鼠）身上进行的，并研究了VEGF-D对淋巴结转移的影响。所有作者都认同VEGF-D的淋巴管生成潜力，但他们注意到VEGF-C诱导的淋巴管生成更优，且有一项研究注意到VEGF-D会诱导血清肿。评估VEGF-D作为淋巴水肿治疗靶向治疗应用的出版物能够证明其淋巴管生成潜力。尽管如此，仍需要进一步研究来调查VEGF-D在淋巴水肿患者治疗中的疗效和安全性。
